TrialLeukemia2023

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.

A S Kubasch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.